Regulatory cells and the effect of cancer immunotherapy
M Iglesias-Escudero, N Arias-González… - Molecular cancer, 2023 - Springer
Several mechanisms and cell types are involved in the regulation of the immune response.
These include mostly regulatory T cells (Tregs), regulatory macrophages (Mregs), myeloid …
These include mostly regulatory T cells (Tregs), regulatory macrophages (Mregs), myeloid …
TGF-β signaling in health, disease, and therapeutics
Z Deng, T Fan, C **ao, H Tian, Y Zheng, C Li… - Signal transduction and …, 2024 - nature.com
Transforming growth factor (TGF)-β is a multifunctional cytokine expressed by almost every
tissue and cell type. The signal transduction of TGF-β can stimulate diverse cellular …
tissue and cell type. The signal transduction of TGF-β can stimulate diverse cellular …
The role of CXCR3 and its ligands in cancer
X Wang, Y Zhang, S Wang, H Ni, P Zhao… - Frontiers in …, 2022 - frontiersin.org
Chemokines are a class of small cytokines or signaling proteins that are secreted by cells.
Owing to their ability to induce directional chemotaxis of nearby responding cells, they are …
Owing to their ability to induce directional chemotaxis of nearby responding cells, they are …
Transcriptome analysis of diffuse large b-cell lymphoma cells inducibly expressing MyD88 L265P mutation identifies upregulated CD44, LGALS3, NFKBIZ, and BATF …
During innate immune responses, myeloid differentiation primary response 88 (MyD88)
functions as a critical signaling adaptor protein integrating stimuli from toll-like receptors …
functions as a critical signaling adaptor protein integrating stimuli from toll-like receptors …
Berberine sensitizes immune checkpoint blockade therapy in melanoma by NQO1 inhibition and ROS activation
Z Luo, Q Li, S He, S Liu, R Lei, Q Kong, R Wang… - International …, 2024 - Elsevier
Unprecedented progress in immune checkpoint blockade (ICB) therapy has been made in
cancer treatment. However, the response to ICB therapy is limited to a small subset of …
cancer treatment. However, the response to ICB therapy is limited to a small subset of …
CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy
B Zhang, J Liu, Y Mo, K Zhang, B Huang… - Frontiers in …, 2024 - frontiersin.org
A steady dysfunctional state caused by chronic antigen stimulation in the tumor
microenvironment (TME) is known as CD8+ T cell exhaustion. Exhausted-like CD8+ T cells …
microenvironment (TME) is known as CD8+ T cell exhaustion. Exhausted-like CD8+ T cells …
Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies
X Peng, J Zheng, T Liu, Z Zhou, C Song… - Current Cancer Drug …, 2024 - ingentaconnect.com
Objective: This review describes the comprehensive portrait of tumor microenvironment
(TME). Additionally, we provided a panoramic perspective on the transformation and …
(TME). Additionally, we provided a panoramic perspective on the transformation and …
The proportion of tumour stroma predicts response to treatment of immune checkpoint inhibitor in combination with chemotherapy in patients with stage IIIB− IV non …
L Yi, Y Wen, M **ao, J Yuan, X Ke, X Zhang… - …, 2024 - Wiley Online Library
Aims Immunotherapy has brought a new era to cancer treatment, yet we lack dependable
predictors for its effectiveness. This study explores the predictive significance of intratumour …
predictors for its effectiveness. This study explores the predictive significance of intratumour …
The Tumor Microenvironment's in Pancreatic Cancer: Effects on Immunotherapy Success and Novel Strategies to Overcome the Hostile Environment
JS Eichhorn, J Petrik - Pathology-Research and Practice, 2024 - Elsevier
Cancer is a significant global health issue that poses a considerable burden on both
patients and healthcare systems. Many different types of cancers exist that often require …
patients and healthcare systems. Many different types of cancers exist that often require …
[HTML][HTML] A novel GARP humanized mouse model for efficacy assessment of GARP-targeting therapies
J Guo, Z Niu, R Lv, J Yuan, Z Zhang, X Guan… - International …, 2024 - Elsevier
Although breakthroughs have been achieved with immune checkpoint inhibitors (ICI)
therapy, some tumors do not respond to those therapies due to primary or acquired …
therapy, some tumors do not respond to those therapies due to primary or acquired …